In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.
With Zoap, Cadillac Rainbow, and Blueberry Caviar. The post Leafly Buzz: 12 hot strains to…
Follow our links to verified aid groups. The post LA’s cannabis community steps up for…
As you might imagine, telling Americans they can't have their guns AND their ganja isn't…
The new ILGM is a veritable treasure trove of expert knowledge that’ll help you find…
edibles, tinctures, beverages, and cannabis oil to name a few. Now, the results of a…
Ask any cannabis enthusiast about their relationship with music while high, and you'll likely get…